Form 4: Pacira BioSciences CAO Executes Stock Sale
Statement of Changes in Beneficial Ownership
Chief Administrative Officer Kristen Williams sold 10,259 shares of Pacira BioSciences following a tax-related share withholding.
Summary
- Kristen Williams, Chief Administrative Officer of Pacira BioSciences, Inc., reported two transactions involving common stock.
- On June 3, 2026, 8,528 shares were withheld by the company to satisfy tax obligations related to the vesting of restricted stock units at a price of $22.32 per share.
- On June 4, 2026, 10,259 shares were sold at an average price of $22.27 per share.
- The sale was executed under a pre-established Rule 10b5-1 trading plan adopted on September 10, 2025.
- Following these transactions, the reporting person maintains beneficial ownership of 167,062 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction was executed under a pre-planned 10b5-1 arrangement, which is a routine administrative action for executives.
Positives
- The sale was conducted via a pre-planned Rule 10b5-1 trading plan, which typically indicates the transaction was not based on non-public material information.
Negatives
- The transaction represents a reduction in the insider's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived by the market as a lack of confidence in near-term stock performance, though this was part of a pre-planned arrangement.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that insider selling via Rule 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and tax obligations, and is generally viewed as neutral by the investment community.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is consistent with standard corporate governance practices for executives at publicly traded biotechnology firms.
Stakeholder Impact
- Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the executive's total holdings.
Key Dates
| Date | Description |
|---|---|
| 2025-09-10 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-06-03 | Date of share withholding for tax obligations. |
| 2026-06-04 | Date of open market sale of common stock. |
| 2026-06-05 | Date of filing. |
Keywords
Pacira BioSciences, PCRX, Insider Trading, Form 4, Rule 10b5-1, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.